Ongoing trials include a phase 3 study comparing Teliso-V with docetaxel in c-MET overexpressing NSCLC and a phase 1B study of Teliso-V as monotherapy or in combination with osimertinib, erlotinib, or nivolumab in c-MET overexpressed/EGFR-mutant metastatic NSCLC [70, 71]. The gene discussed is MET; the disease is non-small cell lung carcinoma.